

WellPoint NextRx Adds Classes of Medications to Cost-of-Care Initiative Program

Effective April 1, 2008, WellPoint NextRx will be adding two new classes of medications, Non-Sedating Antihistamines and Ophthalmic Allergy Agents, to their Cost-of-Care Initiative Program. This program exists in an effort to provide access to affordable, quality prescription care to their members. In addition to the Proton Pump Inhibitors (PPS's) first added to this program in October, 2007, therapeutically equivalent edits will now also be in place for Non-Sedating Antihistamines and Ophthalmic Allergy Agents.

The Non-Sedating Antihistamines include the following brand drugs:

- Allegra susp/Allegro D
- Clarinex/Clarines D
- Semprex D
- Xyzal

The Ophthalmic Allergy Agents include the following brand drugs:

- Alamast
- Alocril
- Alomide
- Elestat
- Emadine
- Optivar
- Patanol

NOTE: Beginning January 21, 2008, Zyrtec and Zyrtec D are scheduled to be available over-the-counter. Therefore, these drugs will no longer be available for coverage under their prescription plans.

If you have any questions, please contact your McGohan Brabender Account Representative at (800) 293-2347.